Hepatitis C (HCV) recurrence after liver transplantation (LT) is universal. The natural history of the recurrence is characterized by rapid fibrosis progression with 20-30% of the patients developing cirrhosis within 5 years of LT . Graft and patient survival are significantly lower in HCV-infected liver transplant recipients as compared to individuals who undergo LT for other indications. Therefore eradication of the virus is an important goal.

Treatment of HCV infection in the peri-transplant setting can be performed in two different situations. First, in patients awaiting LT in order to prevent HCV infection of the graft, and second, in patients with HCV recurrence after LT in whom HCV-related graft damage has already occurred. 

In the recent years there has been a major step forward in the treatment of hepatitis C with the development of new DAA. Results of the studies presented recently prove that hepatitis C can be cured both pre and post liver transplantation in a significant number of patients with minor adverse event. It is probable that hepatitis C will not continued be a major problem of transplant programs.